Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04490057 · ClinicalTrials.gov registry record · Phase 4

A Smart Approach to Treating Tobacco Use Disorder in Persons Living With HIV

A Phase 4 study of Tobacco Use Cessation, sponsored by Yale University.

Completed
Registry status
Phase 4
Development phase
323
Enrollment target
4
Study locations

NCT04490057: Completed Phase 4 study of Tobacco Use Cessation, sponsored by Yale University.

NCT04490057 is a Phase 4 study of Tobacco Use Cessation that has completed, run by Yale University. The registered enrollment target is 323 participants, below the 876-participant average among 36 other Tobacco Use Cessation trials with a reported enrollment target (63% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04490057, a Phase 4 study of Tobacco Use Cessation, has completed, sponsored by Yale University.

COMPLETED
Registry status
Phase 4
Development phase
323 participants
Enrollment target
4
Study locations

Study Summary

Many people living with HIV (PLWH) smoke. Smoking in these individuals is often undertreated. This study plans to assess the ability of various clinical pathways involving tobacco treatment medications and contingency management (paying smokers for not smoking) to improve smoking cessation in a group of PLWH.

Primary Outcome

Self reported reduction in average cigarettes smoked per day at 12 weeks

Conditions Studied

Interventions

  • BEHAVIORAL Contingency Management
  • DRUG Nicotine patch, nicotine gum, nicotine nasal spray, nicotine inhaler
  • DRUG Varenicline or bupropion

Study Locations (4)

Connecticut

  • Bridgeport Hospital Infectious Disease Clinic - Bridgeport
  • Yale University School of Medicine - New Haven

New York

  • SUNY Downstate STAR Clinic - Brooklyn
  • Icahn School of Medicine at Mount Sinai - New York

Trial Details

FieldValue
Enrollment Target 323 participants
Start Date 2020-07-27
Est. Completion 2025-10-24
Phase Phase 4
Yale University

1,492 total trials

What the finished NCT04490057 record still lists

NCT04490057 is an interventional study that assigns participants to a tested intervention. The registered 323 participants enrollment target is mid-sized for trials with a published cap, below the 876-participant average among 36 other Tobacco Use Cessation trials with a reported enrollment target (63% lower).

The record links to 1 condition, with Tobacco Use Cessation appearing as the primary indexed condition, and to 3 interventions - of which Contingency Management is the first listed.

NCT04490057 reports a single indexed study location in Connecticut, New York.

Frequently Asked Questions

What is clinical trial NCT04490057 about?

NCT04490057 is a clinical study titled "A Smart Approach to Treating Tobacco Use Disorder in Persons Living With HIV". Many people living with HIV (PLWH) smoke. Smoking in these individuals is often undertreated. This study plans to assess the ability of various clinical pathways involving tobacco treatment medications and contingency management (paying smokers for not smoking) to improve smoking cessation in a grou...

What is the current status of trial NCT04490057?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 323 participants. The study started on 2020-07-27. Estimated completion is 2025-10-24.

What conditions does trial NCT04490057 study?

This clinical trial studies the following conditions: Tobacco Use Cessation.

What interventions are being tested in trial NCT04490057?

The interventions under investigation include: Contingency Management (BEHAVIORAL), Nicotine patch, nicotine gum, nicotine nasal spray, nicotine inhaler (DRUG), Varenicline or bupropion (DRUG).

Who is sponsoring clinical trial NCT04490057?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04490057 being conducted?

This trial has 4 study locations across Connecticut, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Tobacco Use Cessation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04490057's enrollment target sits among peer trials

323 16th of 36 higher than 21 of 36 other Tobacco Use Cessation trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Tobacco Use Cessation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04164173 · 324 participants · NA

    Hyperinflation Respiratory Therapies in Cardiac Surgery Patients

  • NCT04708054 · 324 participants · Phase 2

    Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

  • NCT05261399 · 324 participants · Phase 3

    Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

  • NCT05353322 · 324 participants · NA

    Breaking up Prolonged Sedentary Behavior to Improve Cardiometabolic Health

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04490057, the US trial registry maintained by the National Library of Medicine. NCT04490057 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.